resubmission second BLA Thank update, the and We morning, call. with appreciate our status everyone. to you, of provide quarter Good We're I'll Greg. everybody joining excited this the start process.
progress CRO the received nearly of the the or did not outstanding for tremendous April CMC items general requirements and any our of the safety validation to continued clinical address with a identify methods. pz-cel.
Since work and release the approval quarterly manufacturing support clinical X clinical and reminder, response FDA in to to that data to ongoing all to call, or have clinical related in make As necessary information request for data and pertaining the now reports we for we've complete in efficacy not last the highlighted The data generated additional BLA the did deficiencies letter certain trials need new testing any CRO items.
the validation, retrovirus integrity of DNA, completed data validation extension closure necessary and deficiencies testing, or [indiscernible] virtual assay, we've work that pertaining to support replication-competent container contract RCR life. whole-cell to product Specifically, testing address importantly, shelf the
to the in noted validation of that namely the our and pleased Type rapid have and assay completed informed runs. data wherein identity the meeting X been the acceptability on the addressed we generated the initiated protocols that CRO. cell-based have the data items, we say finalized our outstanding assay, I'm and A week protocols sterility For of with the the CMC validation we design feasibility several have a preliminary successfully of validation FDA gained last alignment deficiencies
In the that have clarity been the addition, our FDA's cell-based and content materials input identity validation in the for procedures alignment we from also the we pz-cel. now on assays, and minutes has meeting, premeeting responses our validation written of this questions we believe with the on resubmission sterility our on that into gained the FDA and to FDA BLA incorporated Based rapid protocols ongoing. and are for
months to for resubmission. of date BLA We to on the review, set X for accepted resubmission are, BLA PDUFA the from track is expect therefore, a date we the this If resubmit pz-cel FDA year. the
high an gene for Beacon patented We option AAVXXX a targeting Beyond to look AAV-based capsid evaluate announced to the diseases therapies indications progress agreement the allowing in July the in commercialization with on of agreement collaborating select pz-cel, enable to of up potential our and with forward ophthalmology this with eye therapies evaluate efficient and development potential Therapeutics, novel Beacon need. gene to we in believe underscore unmet Beacon for targets. nonexclusive X ophthalmic to AAVXXX's with
underwritten investors we institutional over beyond $XXX of turn milestone our Madhav? and now mention that Vasanthavada our anticipated completed I'll extending Dr. to million runway on an activities. in significant offering commercial Commercial balance update May, Finally, our regulatory cash launch well with Officer, Madhav readiness sheet the to pz-cel.
I'll provide strengthening and call Chief our commercialization
